

Screening for Carbapenemase-producing Enterobacteriaceae following transmission: Experience at a large Victorian healthcare facility

Stephanie Spilsbury & Denise Del Rosario-Kelly
CPE Project Coordinators
Infection Prevention & Hospital Epidemiology
Alfred Health

The authors of this presentation have nil conflicts of interest.

The latest "superbug" What is Carbapenemase-producing Enterobacteriaceae (CPE)?




Overview of CPE

- CPE are Enterobacteriaceae, the largest family of gramnegative bacteria that cause human infection.
- CPE are highly resistant bacteria and are an emerging problem in Australian hospitals.
- CPE are resistant to carbapenems, a class of 'last resort' antibiotics for treating serious infections. The most common way that Enterobacteriaceae become resistant to carbapenems is by producing an enzyme called a carbapenemase.

Overview of CPE

- Enterobacteriaceae are of key importance as human pathogens and as vehicles for the dissemination of antimicrobial resistance because many patients can carry the organism in bowel flora without any adverse harms (colonisation), yet also causing potentially untreatable infections. Furthermore, the carbapenemase resistance gene can easily spread between different species and strains within the Enterobacteriaceae family.
- As most cases represent colonisation, outbreaks are often hidden.
- The increasing resistance of Enterobacteriaceae to most or even all types of antibiotics are a significant global public health threat.


Global distribution of CPE



 Compared with North America, Europe and the Middle East, the number of CPE cases identified in Australia is significantly lower, due in part to our geographical isolation.


(Friedman et al 2017)

CPE in Victoria




Victorian State Guidelines on the management of CPE





Victorian State Guidelines on the management of CPE



Cases by genus and carbapenemase gene group Victoria, 2016

Sherry N, Kwong J, Lane L, et al. ASA Breakpoints. September 2017

Management of CPE - What did we do?

- At Alfred Health, we have 1.0 EFT purely for CPE management, and all up a team comprising of 14 staff.
- We represent the frontline to this public health threat, and we are acutely aware of how challenging the issues are when managing the risk of CPE.



TRA - Intensive Care Unit, The Alfred

• In 2017, the Intensive Care Unit at The Alfred was declared a TRA following the detection of Enterobacter cloacae IMP4 in 3 patients. Subsequent surveys have detected additional cases of CPE.

| Total Patients | 980 |
|------------------|-------------------|
| Deceased | 128 |
| Negative | 520 |
| Not yet screened | 324 |
| Positives | 2 (Same organism) |

TRA - Rehabilitation ward, Caulfield Hospital

• A Rehabilitation ward at Caulfield Hospital was declared a TRA following the detection IMP-4-producing *Enterobacter cloacae* complex in 2017. Following active surveillance for CPE over several weeks, 1 case of CPE was detected.

| Total Patients | 69 |
|------------------|-------------------|
| Deceased | 1 |
| Negative | 54 |
| Not yet screened | 14 |
| Positives | 1 (Same organism) |

Challenges of CPE Management

 By adhering to the Victorian State CPE management guidelines, our capacity to detect and control CPE has increased enormously. However, whilst our management and responses to CPE at our health care facility have helped contain the problem, the threat remains.



Ongoing CPE Management 2017-2018

Following further several cases, we initiated a proactive program (outside of Victorian guidelines) of active screening for high-risk patients for CPE colonisation.

| Indication (2017 - 2018) | Screened | Positive |
|---------------------------------------|----------|-----------|
| ICU Point Prevalence Screening | 707 | 3 |
| ICU Discharge Screening | 2476 | 6 |
| ICU Ward Contacts | 952 | 5 |
| Other Ward Point Prevalence Screening | 269 | 2 |
| TOTAL | 4404 | 16 (0.4%) |

Thank you

